Abarceo Pharma

Abarceo Pharma is a Swedish, preclinical-stage biotechnology company founded on pioneering research from Lund University. Its core technology targets the mitochondrial protein VDAC1, aiming to reverse beta-cell dysfunction in Type 2 Diabetes and potentially treat other conditions like Alzheimer's Disease and cardiovascular disease. The company is led by a CEO with entrepreneurial experience and founded by world-renowned diabetes researchers, positioning it to address multi-billion-euro markets with high unmet need. Abarceo is currently establishing preclinical proof-of-concept across its initial target indications.

Small molecule platform targeting the mitochondrial protein VDAC1 to restore mitochondrial function and cellular health, initially focused on pancreatic beta cells in Type 2 Diabetes.

Competition in T2D is intense, but most therapies manage symptoms; few aim to restore beta-cell function. In mitochondrial medicine, several companies are exploring different targets, but VDAC1-focused approaches appear nascent. Abarceo's first-mover scientific insight provides a potential edge, but it will compete for funding and talent in a crowded biotech ecosystem.